A review of the impact of photon and proton external beam radiotherapy treatment modalities on the dose distribution in field and out-of-field; implications for the long-term morbidity of cancer survivors

Acta Oncologica

Volumn 46, Issue 4, 2007, Pages 462-473

  Palm, Åsa ^a   Johansson, Karl Axel ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER SURVIVOR; COMPUTER ASSISTED TOMOGRAPHY; DATA ANALYSIS; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; MONTE CARLO METHOD; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARANASAL SINUS CANCER; PHOTON THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; RADIATION DOSE DISTRIBUTION; RADIATION FIELD; RECTUM CANCER; REVIEW; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME;

DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; NEOPLASMS; NEOPLASMS, SECOND PRIMARY; PHOTONS; PROTONS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; SURVIVORS;

EID: 34248551179     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860701218626     Document Type: Review

References (56)

1. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:1204-16.
2. Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, et al. The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2005;62:1195-203.
3. Stovall M, Blackwell CR, Cundiff J, Novack DH, Palta JR, Wagner LK, et al. Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36. Med Phys 1995;22:63-82.
4. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999;353(9149):267-72.
5. Wolden SL, Chen WC, Pfister DG, Kraus DH, Berry SL, Zelefsky MJ. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: Update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol Biol Phys 2006;64:57-62.
6. Zelefsky MJ, Fuks Z, Happersett L, Lee HJ, Ling CC, Burman CM, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol 2000;55:241-9.
7. Glimelius B, Ask A, Bjelkengren G, Bjork-Eriksson T, Blomquist E, Johansson B, et al. Number of patients potentially eligible for proton therapy. Acta Oncol 2005;44:836-49.
8. Cella L, Lomax A, Miralbell R. Potential role of intensity modulated proton beams in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2001;49:217-23.
9. Johansson J, Blomquist E, Montelius A, Isacsson U, Glimelius B. Potential outcomes of modalities and techniques in radiotherapy for patients with hypopharyngeal carcinoma. Radiother Oncol 2004;72:029-38.
10. Cozzi L, Fogliata A, Lomax A, Bolsi A. A treatment planning comparison of 3D conformal therapy, intensity modulated photon therapy and proton therapy for treatment of advanced head and neck tumours. Radiother Oncol 2001;61:287-97.
11. Mu X, Bjork-Eriksson T, Nill S, Oelfke U, Johansson KA, Gagliardi G, et al. Does electron and proton therapy reduce the risk of radiation induced cancer after spinal irradiation for childhood medulloblastoma? A comparative treatment planning study. Acta Oncol 2005;44:554-62.
12. Weber DC, Trofimov AV, Delaney TF, Bortfeld T. A treatment planning comparison of intensity modulated photon and proton therapy for paraspinal sarcomas. Int J Radiat Oncol Biol Phys 2004;58:1596-606.
13. Van der Giessen PH. A simple and generally applicable method to estimate the peripheral dose in radiation teletherapy with high energy x-rays or gamma radiation. Int J Radiat Oncol Biol Phys 1996;35:1059-68.
14. Stovall M, Blackwell CR, Cundiff J, Novack DH, Palta JR, Wagner LK, et al. Erratum: "Fetal dose from radiotherapy with photon beams: Report of AAPM Radiation Therapy Committee Task Group No. 36"Med Phys 1995;22:63-82]. Med Phys 1995;22:1353-4.
15. Jordan TJ. Central axis depth dose data for use in radiotherapy Section 5: Megavoltage X-ray beams: 2-50 MV. Br J Radiol 1996;(Suppl 25):62-109.
16. Epstein RJ, Kelly SA, Cook M, Bateman A, Paddick I, Kam KC, et al. Active minimisation of radiation scatter during breast radiotherapy: Management implications for young patients with good-prognosis primary neoplasms. Radiother Oncol 1996;40:69-74.
17. Mutic S, Esthappan J, Klein EE. Peripheral dose distributions for a linear accelerator equipped with a secondary multileaf collimator and universal wedge. J Appl Clin Med Phys 2002;3:302-9.
18. Mutic S, Klein EE. A reduction in the AAPM TG-36 reported peripheral dose distributions with tertiary multileaf collimation. American Association of Physicists in Medicine Task Group 36. Int J Radiat Oncol Biol Phys 1999;44:947-53.
19. Stern RL. Peripheral dose from a linear accelerator equipped with multileaf collimation. Med Phys 1999;26:559-63.
20. Mazonakis M, Varveris H, Fasoulaki M, Damilakis J. Radiotherapy of Hodgkin's disease in early pregnancy: Embryo dose measurements. Radiother Oncol 2003;66:333-9.
21. Sharma DS, Animesh, Deshpande SS, Phurailatpam RD, Deshpande DD, Shrivastava SK, et al. Peripheral dose from uniform dynamic multileaf collimation fields: Implications for sliding window intensity-modulated radiotherapy. Br J Radiol 2006;79(940):331-5.
22. Petti PL, Chuang CF, Smith V, Larson DA. Peripheral doses in CyberKnife radiosurgery. Med Phys 2006;33:1770-9.
23. Jeraj R, Mackie TR, Balog J, Olivera G, Pearson D, Kapatoes J, et al. Radiation characteristics of helical tomotherapy. Med Phys 2004;31:396-404.
24. Ramsey CR, Seibert R, Mahan SL, Desai D, Chase D. Out-of-field dosimetry measurements for a helical tomotherapy system. J Appl Clin Med Phys 2006;7:1-11.
25. Meeks SL, Paulino AC, Pennington EC, Simon JH, Skwarchuk MW, Buatti JM. In vivo determination of extra-target doses received from serial tomotherapy. Radiother Oncol 2002;63:217-22.
26. Mutic S, Low DA. Whole-body dose from tomotherapy delivery. Int J Radiat Oncol Biol Phys 1998;42:229-32.
27. Reft CS, Runkel-Muller R, Myrianthopoulos L. In vivo and phantom measurements of the secondary photon and neutron doses for prostate patients undergoing 18MV IMRT. Med Phys 2006;33:3734-42.
28. Roy SC, Sandison GA. Shielding for neutron scattered dose to the fetus in patients treated with 18 MV x-ray beams.Med Phys 2000;27:1800-3.
29. Binns PJ, Hough JH. Secondary dose exposures during 200 MeV proton therapy. Radiat Prot Dosim 1997;70:441-4.
30. Mesoloras G, Sandison GA, Stewart RD, Farr JB, Hsi WC. Neutron scattered dose equivalent to a fetus from proton radiotherapy of the mother. Med Phys 2006;33:2479-90.
31. Polf JC, Newhauser WD. Calculations of neutron dose equivalent exposures from range-modulated proton therapy beams. Phys Med Biol 2005;50:3859-73.
32. Roy SC, Sandison GA. Scattered neutron dose equivalent to a fetus from proton therapy of the mother. Radiat Phys Chem 2004;71:997-8.
33. Schneider U, Agosteo S, Pedroni E, Besserer J. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 2002;53:244-51.
34. Yan X, Titt U, Koehler AM, Newhauser WD. Measurement of neutron dose equivalent to proton therapy patients outside of the proton radiation field. Nuclear Inst Methods Phys Res A 2002;476:429-34.
35. Agosteo S, Birattari C, Caravaggio M, Silari M, Tosi G. Secondary neutron and photon dose in proton therapy. Radiother Oncol 1998;48:293-305.
36. Jiang H,Wang B, Xu XG, Suit HD, Paganetti H. Simulation of organ-specific patient effective dose due to secondary neutrons in proton radiation treatment. Phys Med Biol 2005;50:4337-53.
37. Howell RM, Hertel NE, Wang Z, Hutchinson J, Fullerton GD. Calculation of effective dose from measurements of secondary neutron spectra and scattered photon dose from dynamic MLC IMRT for 6MV, 15 MV, and 18 MV beam energies. Med Phys 2006;33:360-8.
38. Vanhavere F, Huyskens D, Struelens L. Peripheral neutron and gamma doses in radiotherapy with an 18 MV linear accelerator. Radiat Prot Dosimetry 2004;110:607-12.
39. Durante M, Yamada S, Ando K, Furusawa Y, Kawata T, Majima H, et al. Measurements of the equivalent whole-body dose during radiation therapy by cytogenetic methods. Phys Med Biol 1999;44:1289-98.
40. Followill D, Geis P, Boyer A. Estimates of whole-body dose equivalent produced by beam intensity modulated conformal therapy. Int J Radiat Oncol Biol Phys 1997;38:667-72.
41. Goddu S, Mutic S, Grigsby J, Santanam L, Low D. Wholebody dose for helical tomotherapy. Med Phys 2006;33:2150.
42. Verellen D, Vanhavere F. Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region. Radiother Oncol 1999;53:199-203.
43. Glimelius B, Isacsson U, Blomquist E, Grusell E, Jung B, Montelius A. Potential gains using high-energy protons for therapy of malignant tumours. Acta Oncol 1999;38:137-45.
44. Ahsan H, Neugut AI. Radiation therapy for breast cancer and increased risk for esophageal carcinoma. Ann Intern Med 1998;128:114-7.
45. Boice JD, Jr, Day NE, Andersen A, Brinton LA, Brown R, Choi NW, et al. Second cancers following radiation treatment for cervical cancer. An international collaboration among cancer registries. J Natl Cancer Inst 1985;74:955-75.
46. Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000;88:398-406.
47. Hall EJ, Wuu CS. Radiation-induced second cancers: The impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003;56:83-8.
48. Zelefsky MJ, Chan H, Hunt M, Yamada Y, Shippy AM, Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 2006;176:1415-9.
49. Aoyama H, Westerly DC, Mackie TR, Olivera GH, Bentzen SM, Patel RR, et al. Integral radiation dose to normal structures with conformal external beam radiation. Int J Radiat Oncol Biol Phys 2006;64:962-7.
50. Johansson J. Thesis: Comparative treatment planning in radiotherapy and clinical impact of proton relative biological effectiveness. Uppsala: Acta Universitatis Upsaliensis; 2006.
51. Johansson J, Isacsson U, Lindman H, Montelius A, Glimelius B. Node-positive left-sided breast cancer patients after breast-conserving surgery: Potential outcomes of radiotherapy modalities and techniques. Radiother Oncol 2002;65:89-98.
52. Lomax AJ, Bortfeld T, Goitein G, Debus J, Dykstra C, Tercier PA, et al. A treatment planning inter-comparison of proton and intensity modulated photon radiotherapy. Radiother Oncol 1999;51:257-71.
53. Lomax AJ, Cella L, Weber D, Kurtz JM, Miralbell R. Potential role of intensity-modulated photons and protons in the treatment of the breast and regional nodes. Int J Radiat Oncol Biol Phys 2003;55:785-92.
54. Mock U, Bogner J, Georg D, Auberger T, Potter R. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlenther Onkol 2005;181:448-55.
55. Mock U, Georg D, Bogner J, Auberger T, Potter R. Treatment planning comparison of conventional, 3D conformal, and intensity-modulated photon (IMRT) and proton therapy for paranasal sinus carcinoma. Int J Radiat Oncol Biol Phys 2004;58:147-54.
56. Pirzkall A, Carol M, Lohr F, Hoss A, Wannenmacher M, Debus J. Comparison of intensity-modulated radiotherapy with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol Biol Phys 2000;48:1371-80.